🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Brooks Laboratories Limited BROOKS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.brookslabs.net
Company Profile ↓
₹66.07
-55.59% 1Y
Mkt Cap₹194.62 Cr
P/E14.71
P/B1.51
52W High₹159.04
52W Low₹37.11
Book Value₹41.64
EPS (TTM)₹4.49

Company Overview

Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, pain management, controlled drugs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, the Democratic Republic of Congo, Angola, Mozambique, Latin America, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.1%.

Consistent Profit Growth

Net profit has compounded at 72.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.1% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 14.7, below the sector median of 40.0.

Healthy Margins

Maintains a net profit margin of 15.9%.

Recent Developments

  • Mar 2026 Revenue of ₹85.74 Cr (+3.9% YoY); net profit ₹24.58 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -10.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.1%, profit CAGR 72.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.12%
1 Year:-10.00%

Compounded Profit Growth

5 Years:72.56%
1 Year:-

Stock Price Performance

1 Year:-55.59%
6 Months:+8.31%
3 Months:-3.17%
1 Month:+10.02%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 24% of range
₹37.11 ₹159.04
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)55.73 · Neutral
Price Performance
1M+10.02%
3M-3.17%
6M+8.31%
1Y-55.59%
Valuation vs Sector

P/E of 14.71 is below the sector median of 40.02 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.0%.
  • Healthy ROCE of 20.1%.
  • Compounding revenue at 11.1% over 5 years.
  • Profit CAGR of 72.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 58.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
14.71
Industry PE
40.02
Forward P/E
11.37
PEG Ratio
-
Book Value
₹41.64
Price to Book
1.51
P/S
2.23
EV/EBITDA
31.38
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
11.12%
Profit 5Y
72.56%
Revenue (YoY)
-10.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
20.12%
ROE
20.04%
ROA
16.59%
Profit Margin
15.88%
Op Margin
6.30%
Gross Margin
41.44%
EPS (Latest Qtr)
₹0.52
EPS (TTM)
₹4.49

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
1.21
Current Ratio
1.72
Debt
₹8.52 Cr
Total Assets
₹148.17 Cr
Current Assets
₹37.42 Cr
Working Capital
₹15.60 Cr

Ownership

Promoter Holding
55.88%
Chg in Prom Hold
0.00%
FII / Inst Holding
9.90%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
₹194.62 Cr
Total Revenue (TTM)
₹83.19 Cr
EBITDA
₹5.97 Cr
Free Cash Flow
₹5.79 Cr
Operating Cash Flow
₹9.29 Cr
Shares Outstanding
₹2.95 Cr
Gross Margin
41.44%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BROOKS Brooks Laboratories Limited NSEPHARMA 66.07 14.71 ₹194.62 Cr 0.00% 20.12% 20.04% 11.12% 72.56%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,895.00 37.64 ₹4.55 L Cr 0.85% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,315.00 84.60 ₹2.47 L Cr 0.31% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,914.00 78.62 ₹1.87 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.23% 19.20% 20.48% 14.85% 33.34%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 688.00 237.24 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,156.90 23.10 ₹1.16 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 33.25 ₹1.12 L Cr 0.94% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 90.86 ₹99,417.45 Cr 0.12% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -23.32 Cr25.51 Cr23.45 Cr16.57 Cr20.21 Cr
Cost of Revenue -15.81 Cr15.89 Cr13.71 Cr9.00 Cr12.42 Cr
Gross Profit -7.51 Cr9.62 Cr9.74 Cr7.57 Cr7.79 Cr
Operating Expenses -6.35 Cr6.88 Cr7.61 Cr7.23 Cr7.53 Cr
Operating Income -1.15 Cr2.73 Cr2.13 Cr33.91 L26.52 L
EBITDA --63.39 L10.28 Cr8.65 Cr6.05 Cr2.02 Cr
Interest Expense -26.11 L30.14 L28.34 L16.13 L8.92 L
Pretax Income --1.28 Cr9.58 Cr7.98 Cr5.50 Cr1.52 Cr
Tax Provision -17.54 L0000
Net Income --1.46 Cr9.58 Cr7.98 Cr5.50 Cr1.52 Cr
Diluted EPS --0.543.252.711.870.52

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -62.48 Cr79.01 Cr82.56 Cr85.74 Cr
Cost of Revenue -61.22 Cr61.06 Cr54.07 Cr51.02 Cr
Gross Profit -1.26 Cr17.95 Cr28.48 Cr34.72 Cr
Operating Expenses -34.81 Cr16.50 Cr25.15 Cr29.25 Cr
Operating Income --33.55 Cr1.45 Cr3.34 Cr5.47 Cr
EBITDA --29.39 Cr-17.07 Cr-7.16 Cr27.01 Cr
Interest Expense -1.95 Cr72.47 L1.03 Cr83.53 L
Pretax Income --38.37 Cr-19.57 Cr-9.79 Cr24.58 Cr
Tax Provision --7.32 Cr2.59 L17.54 L0
Net Income --20.89 Cr-19.59 Cr-9.97 Cr24.58 Cr
Diluted EPS --12.57-7.67-3.728.35

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -109.60 Cr90.45 Cr123.69 Cr148.17 Cr
Current Assets -27.61 Cr31.05 Cr33.88 Cr37.42 Cr
Cash & Equivalents -2.32 L12.55 L4.34 L6.59 Cr
Inventory -11.30 Cr9.61 Cr9.20 Cr11.02 Cr
Receivables -12.75 Cr16.32 Cr19.99 Cr16.11 Cr
Total Liabilities -35.64 Cr24.86 Cr25.59 Cr25.52 Cr
Current Liabilities -33.02 Cr23.05 Cr22.84 Cr21.81 Cr
Long Term Debt -0013.05 L1.19 Cr
Total Debt -6.51 Cr5.64 Cr7.58 Cr8.52 Cr
Total Equity -73.95 Cr65.59 Cr98.10 Cr122.66 Cr
Shares Outstanding -2.49 Cr2.62 Cr2.95 Cr2.95 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --14.49 Cr-9.80 Cr2.63 Cr9.29 Cr
Investing Cash Flow -49.49 L18.22 L-45.14 Cr-2.92 Cr
Financing Cash Flow -11.41 Cr9.72 Cr42.43 Cr17.09 L
Capital Expenditure --46.75 L-43.88 L-92.28 L-3.51 Cr
Free Cash Flow --14.96 Cr-10.24 Cr1.70 Cr5.79 Cr
Net Change in Cash --2.58 Cr10.23 L-8.21 L6.54 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -2.0%22.7%34.5%40.5%
Operating Margin % --53.7%1.8%4.0%6.4%
Net Margin % --33.4%-24.8%-12.1%28.7%
ROE % --28.3%-29.9%-10.2%20.0%
ROCE % --43.8%2.2%3.3%4.3%

Shareholding Pattern

Insiders
55.88%
Institutions
9.90%
Public Float
22.44%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BROOKS

Google News Sat, 05 Sep 2026

Jonathon Brooks' Stock Back on the Rise Amidst Improved Health Outlook - NFL News | Fantasy Football - RotoBaller

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNZ0pITmxqV0JYV1pTRk9QNmd2SjRZX0ltSkZXcUhRam11NXlmWXhXaW50WEtWWjl5ZXQtSUR0R0hUTUFGaWpORmc4YXo3amVRcHp6Mm9HUjV2N3BDM1ItYmtsajZwS1RNQm9mSVl2N3k0Si1xbXNGeTBKdUduNmxfQXFhU0Ezd1IyaXluWU…

Google News Fri, 04 Sep 2026

Berenberg Bank Forecasts Strong Price Appreciation for Brooks Macdonald Group (LON:BRK) Stock - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNTEVZemhKczlhR0Z5OFp3QVZRdWFZeWd0d0JPNkVWWUU0N2l2OE1vRTJkVzRCNWdUZnVrN1dYMXlKOTlEaWFKV3dzMGlkOGtFQ0pQQkxZRnd6YVY2NTZvenJ3c3ZDUEV3UlU3dmZBOUNFcDZ4UVFFaHQzUWlCU0R2SnRRQlZkUXplOEd6el…

Google News Mon, 17 Aug 2026

Dolphins Stock Report (Day 13): How long will Jordyn Brooks be sidelined? - Yahoo Sports

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNemFWOHZWdlR0WlJlZEVVRmkzQWRhYTJWM3lnU2JHZ1hMQ0lidlRRb0dBWHI5NG5mMTBvUjVPX21kWklCOXZIRUVWcVVVTW1KSmlXd0N1YnJWM2JWUG9zTVpjRkhDYnFCek05ZlpLQmwyNG9wRGZqSHRMNlpYN0RrVGdUYw?oc=5" targe…

Google News Sat, 15 Aug 2026

Panthers RB Jonathon Brooks is Rapidly Replacing Chuba Hubbard in Fantasy Football - Sports Illustrated

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWTBKLS0yanAwaFZmQ0hOSFVuX1UtNXQ2SlpPTnFGdEZ2Z0RTS2E1VlM3RGZtb1dvbFpDdzMzUkoydjBINmdBUWZiVEpwYjJQWUFwa3J5b3BFdlphUHk0Y2NDX21wbFcybGVzY3N5eUJoOGZZUno0MW9lNmV6NFY1TEhicDB3bWppMHRERn…

Google News Fri, 08 May 2026

PAC retracts 'insider stock trading' ad – but Mo Brooks' STOCK Act violation over pandemic-era Pfizer trades while in office remains - Yellowhammer News

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOUGRENVZpR3ZMN0syTGhyVHNRZHNrZF9iN0hqZGVYbkJlbTJHeUJYR085a0pjUVdWUS1xVXVBS3lKOXFBMUFtbkV1U1R4QVpHVVdaOTBqZDAwb3o3b1pFNW9jLWtqNnpLdmFsdzkyaEFUWWg4azBTM1Z6NzVHaEhTYnZjTzlqUFpvR3g3Yl…

Google News Wed, 22 Jul 2026

UK Stocks an Underappreciated AI Play, Brooks Macdonald CIO Says - bloomberg.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxORE5udXJ0Z09lakFPc1BtcDRKT2dXdHBkY0lxZEVDRTd4aWhfeF84emV6WUxscnRZXzl0VUJxdFlHTlpaOUxIaGdqS0t5QzNLNWI4WWRSN1c5R2Qtd01YcU9LN2FkQXpWckUzVGpJTW1WQzlwRFpaQ0RfQ0U3NWZCR1RyLV9DVkM5TmMxTn…

BROOKS — Frequently Asked Questions

What is the current share price of Brooks Laboratories Limited (BROOKS)?

As of 2026-09-20 09:43 IST, Brooks Laboratories Limited (BROOKS) trades at ₹66.07 on NSE. Its 52-week range is ₹37.11 to ₹159.04.

What is the market capitalisation of BROOKS?

Brooks Laboratories Limited (BROOKS) has a market capitalisation of ₹194.62 Cr on NSE.

What is the P/E ratio of BROOKS?

BROOKS trades at a trailing price-to-earnings (P/E) ratio of 14.71. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 1.51.

What is the return on equity (ROE) of BROOKS?

BROOKS has a return on equity (ROE) of 20.04%. Its return on capital employed (ROCE) is 20.12%.

Is BROOKS a good stock to buy?

This page provides a data-driven analysis of Brooks Laboratories Limited (BROOKS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space